Since triple-negative breast cancer (TNBC) lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2), therapeutic options for TNBC are limited and leaving poor prognosis. This evidence concerns the gene PGR and triple-negative breast carcinoma.